
    
      This study is a single-center phase II randomized clinical trial to enroll low-risk breast
      cancer treat with breast-conserving surgery. All eligible patients are randomized to receive
      either ABPI (40Gy/10fx/2wks) or WBI(43.5Gy/15fx/3wks). Intensity modulated radiation therapy
      (IMRT) technique is used. Grade 2 or more acute and late toxicities are prospectively
      evaluated and compared.
    
  